Hypertension treatment commonly uses which class pairs?

Hypertension treatment commonly uses which class pairs?

• A. ACE inhibitors and Angiotensin II antagonists
• B. Beta-blockers and calcium channel blockers
• C. Diuretics and vasodilators
• D. Alpha blockers and nitrates

Answer: (A)

The key idea is that blocking the renin–angiotensin–aldosterone system (RAAS) is a central strategy in lowering blood pressure. ACE inhibitors and angiotensin II receptor blockers both target this pathway, but in different ways. ACE inhibitors stop the conversion of angiotensin I to angiotensin II, which reduces vasoconstriction and lowers aldosterone-driven fluid retention. ARBs, on the other hand, block angiotensin II from binding its receptor, achieving similar effects. Because they attack the same hormonal system—one by preventing production and the other by blocking action—they are among the most commonly used first-line choices and provide notable cardiovascular and kidney protection in many patients. They are typically used as alternatives to each other depending on tolerance (for example, cough with ACE inhibitors or hyperkalemia risk with either class), rather than being combined together. The other pairings involve drugs that are used in hypertension but do not represent this central RAAS-blocking approach as clearly or consistently as a first-line strategy.

The key idea is that blocking the renin–angiotensin–aldosterone system (RAAS) is a central strategy in lowering blood pressure. ACE inhibitors and angiotensin II receptor blockers both target this pathway, but in different ways. ACE inhibitors stop the conversion of angiotensin I to angiotensin II, which reduces vasoconstriction and lowers aldosterone-driven fluid retention. ARBs, on the other hand, block angiotensin II from binding its receptor, achieving similar effects. Because they attack the same hormonal system—one by preventing production and the other by blocking action—they are among the most commonly used first-line choices and provide notable cardiovascular and kidney protection in many patients. They are typically used as alternatives to each other depending on tolerance (for example, cough with ACE inhibitors or hyperkalemia risk with either class), rather than being combined together. The other pairings involve drugs that are used in hypertension but do not represent this central RAAS-blocking approach as clearly or consistently as a first-line strategy.